Assenagon Asset Management S.A. Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Assenagon Asset Management S.A. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 0.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 650,679 shares of the medical device company's stock after purchasing an additional 3,833 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.17% of DexCom worth $44,435,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of DexCom during the fourth quarter worth about $385,367,000. Congress Asset Management Co. grew its holdings in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD purchased a new position in shares of DexCom during the fourth quarter worth about $96,507,000. Woodline Partners LP purchased a new position in shares of DexCom during the fourth quarter worth about $63,338,000. Finally, Northern Trust Corp grew its holdings in shares of DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after buying an additional 753,857 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on DXCM shares. The Goldman Sachs Group started coverage on DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Wall Street Zen upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Citigroup restated a "buy" rating and issued a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Robert W. Baird reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $98.50.

DexCom Price Performance

Shares of DXCM stock traded up $1.01 during midday trading on Monday, reaching $83.00. 3,446,203 shares of the company traded hands, compared to its average volume of 4,346,742. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm's 50 day simple moving average is $78.95 and its two-hundred day simple moving average is $79.36. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.91. The firm has a market cap of $32.54 billion, a PE ratio of 58.04, a price-to-earnings-growth ratio of 2.30 and a beta of 1.46.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period last year, the business earned $0.32 earnings per share. The company's revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president now directly owns 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.